Where does AnaptysBio, Inc.'s cash flow data come from?

Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

AnaptysBio, Inc. ANAB Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	-$84.63M+48.9%	-$132.59M+22.1%	-$140.62M+13.9%
Depreciation and amortization	$543K-7.8%	$559K-7.8%	$573K-8.5%	$577K-9.8%	$589K-9.2%
Stock-based compensation	$41.12M+24.3%	$36.07M+5.9%	$35.75M+5.2%	$34.78M+3.5%	$33.09M-4.0%
Deferred income taxes	——	——	——	——	——
Change in accounts payable	-$81.11M-53.9%	-$87.33M-158%	-$104.96M—	-$83.04M—	-$52.7M—
Change in other assets	——	——	——	-$2.65M—	-$5.3M—
Other working capital changes	——	——	$6.42M+145%	$13.52M+530%	$17.35M+403%
Net gains (losses) on investments	$3.08M-65.9%	$4.73M-54.1%	$6.7M-40.0%	$8.13M-29.8%	$9.01M-20.2%
Non-cash operating lease expense	$1.88M+4.1%	$1.86M+4.1%	$1.85M+4.0%	$1.83M+4.0%	$1.81M+4.0%
Change in operating lease liabilities	-$1.96M-8.2%	-$1.93M-8.3%	-$1.89M-8.5%	-$1.85M-8.4%	-$1.81M-8.5%
Net cash from operating activities	$4.48M+104%	$19.7M+115%	-$144.97M-40.7%	-$127.71M+1.3%	-$108.78M+18.5%
Capital expenditures	$69K-81.1%	$87K-75.7%	$349K-6.9%	$372K-25.9%	$366K-44.5%
Purchases of investments	$73.86M-83.4%	$196.41M-48.4%	$317.29M-2.6%	$348.98M+1.3%	$443.93M+41.2%
Proceeds from maturities/sales of investments	$322.1M-33.7%	$424.53M-10.8%	$442.78M-11.5%	$429.83M-12.5%	$485.92M+9.7%
Net cash from investing activities	$248.17M—	$228.03M—	——	——	——
Repurchases of common stock	$64.2M+1,216%	$68.63M+14,950%	$65.7M—	$55.98M—	$4.88M—
Proceeds from issuance of common stock	$27.99M+370%	$14.26M+120%	$2.6M-57.9%	$6.4M+189%	$5.95M+195%
Taxes paid for net share settlement	——	——	——	——	——
Net cash from financing activities	-$102.81M-192%	-$132.61M-204%	-$61.91M-166%	$19.71M-1.6%	$112.1M+417%
Net increase (decrease) in cash	$149.83M—	$115.12M—	——	——	——
Interest paid	$82.73M+37.3%	$79.99M+89.9%	$99.06M—	$78.04M—	$60.23M—
Increase (Decrease) in Contract with Customer, Asset	——	——	——	——	$10.8M+93.9%
Increase (Decrease) in Deferred Income Taxes	——	——	——	——	——
Operating lease liabilities	-$1.96M-8.2%	-$1.93M-8.3%	-$1.89M-8.5%	-$1.85M-8.4%	-$1.81M-8.5%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	-$2.65M—	-$5.3M—
Noncash Advance Future Royalties Interest Expense	——	——	——	——	$55.63M+112%
Operating lease right-of-use asset amortization	$1.88M+4.1%	$1.86M+4.1%	$1.85M+4.0%	$1.83M+4.0%	$1.81M+4.0%
Proceeds From Sale And Maturity Of Available For Sale Securities	$322.1M-33.7%	$424.53M-10.8%	$442.78M-11.5%	$429.83M-12.5%	$485.92M+9.7%
Payments Of Advance Future Royalties Issuance Costs	——	$0-100%	$25.75K-70.7%	$51.5K-29.5%	$77.25K+33.2%
Repayment Of Advance Future Royalty And Milestones	$66.6M—	$76.8M—	——	——	——
Accrued payables for capital expenditures	——	——	——	——	$18K—
Increase Decrease In Operating Lease Liability	-$1.96M-8.2%	-$1.93M-8.3%	-$1.89M-8.5%	-$1.85M-8.4%	-$1.81M-8.5%
Unrealized Gain (Loss) on Investments	$3.08M-65.9%	$4.73M-54.1%	$6.7M-40.0%	$8.13M-29.8%	$9.01M-20.2%
Total state income taxes, net of refunds	——	——	——	——	$5K—
Receivables For Stock Options Exercised	——	——	$452K—	-$29K—	$0—
Repurchase Of Common Stock Incurred But Not Yet Paid	——	——	——	——	$959K—
Free cash flow	$4.41M+104%	$19.61M+114%	-$145.32M-40.6%	-$128.08M+1.4%	-$109.15M+18.6%
Free cash flow	$4.41M+104%	$19.61M+114%	-$145.32M-40.6%	-$128.08M+1.4%	-$109.15M+18.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does AnaptysBio, Inc.'s cash flow data come from?: Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.